Chengdu Olymvax Soars 15.06%, Hits Intraday High of CNY 31.26

Chengdu Olymvax Biopharmaceuticals, Inc. has experienced significant activity today, with the stock surging by 15.06% on March 18, 2026. The stock reached an intraday high of CNY 31.26, reflecting strong market performance. Over the past year, the company has demonstrated impressive growth, achieving a remarkable 109.54% increase, significantly outperforming the China Shanghai Composite, which rose by only 18.46% during the same period. In addition to its strong annual performance, Chengdu Olymvax has shown resilience in the short term, with a 2.57% increase over the past week, while the broader market declined by 1.7%. The company's net sales growth of 25.38% and positive results for the last two consecutive quarters highlight its robust operational performance. Financial metrics further underscore the company's stability, with a return on equity of 6.56% and a low debt-to-equity ratio of 0.18. The stock's performance indicates a strong position within the pharmaceuticals and biotechnology sector, making it a noteworthy player in the mid-cap market.